Cinaciguat
- Generic Name
- Cinaciguat
- Drug Type
- Small Molecule
- Chemical Formula
- C36H39NO5
- CAS Number
- 329773-35-5
- Unique Ingredient Identifier
- 59K0Y58UAD
- Background
Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)).
A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
Phase 2
Terminated
- Conditions
- Acute Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-12
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5
- Registration Number
- NCT01067859
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
Phase 2
Terminated
- Conditions
- Acute Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT01065077
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
Phase 2
Terminated
- Conditions
- Heart FailureHeart Decompensation
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 62
- Registration Number
- NCT01064037
Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667
Phase 2
Terminated
- Conditions
- Congestive Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT00559650
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath